Thymalin Protocol: Complete Cycling & Dosing Guide

Overview

Thymalin is a polypeptide complex extracted from bovine thymus tissue, consisting of short-chain peptides including thymopoietin fragments and other thymic factors. It functions as an immunomodulator by promoting T-lymphocyte differentiation and maturation while modulating cytokine production (IL-1, IL-2, interferon-gamma). The compound is administered via injection and is extensively used in Eastern European clinical practice for immune restoration, age-related immune decline, and as a cytoprotective agent.

Unlike compounds designed primarily for muscle building or fat loss, thymalin's evidence base concentrates on immune function, longevity, and inflammatory control. Its strongest human evidence supports mortality reduction in elderly populations (2.0-2.1 fold reduction over 6-8 years) and improved outcomes in inflammatory and infectious disease states. The compound exhibits a favorable safety profile across decades of Eastern European use, though regulatory approval remains limited outside these regions.

Important: This guide is educational content only and does not constitute medical advice. Thymalin's regulatory status varies by country and is not FDA or EMA approved. Consult with a physician before use, particularly if you have autoimmune conditions, are an organ transplant recipient, or have active hematologic malignancies.

Standard Protocol

The foundational thymalin protocol follows a straightforward structure optimized for immune restoration without excessive immune overstimulation.

Dosing Range: 5–20 mg once daily via intramuscular or subcutaneous injection

Recommended Starting Dose: 10 mg daily for general immune support

Cycle Length: 10–30 days on, followed by 10–30 days off

Most Common Protocol: 10 mg daily for 20 days, then 20 days off (represents one complete cycle)

The standard protocol works through pulsed immune activation. Rather than continuous daily use, cycling prevents immune tolerance and allows the thymus and T-lymphocyte populations to respond robustly during the "on" phase, then consolidate gains during the "off" phase. Most practitioners report that cycling 20 days on/20 days off provides an optimal balance between efficacy and safety while minimizing injection site irritation from prolonged daily administration.

Goal-Specific Protocols

Immune Support & General Health (Primary Indication)

Cycle Structure: 10 mg daily × 20 days, then 20 days off

Repeat: 3–4 cycles per year (spacing across seasons is common practice)

Rationale: This moderate-dose protocol emphasizes T-lymphocyte restoration without aggressive immune activation. It suits individuals managing chronic infections, post-infection immune recovery, or general age-related immune decline.

Markers to Monitor: T-lymphocyte counts (especially CD4+/CD8+ ratio), lymphocyte percentage in CBC, clinical infection frequency

Longevity & Age-Related Decline

Cycle Structure: 10 mg daily × 30 days, then 30 days off

Repeat: 2–3 cycles yearly, potentially continuing long-term with breaks

Dosing Notes: The strongest longevity evidence comes from a 6–8 year observational study (n=266) showing 2.0–2.1 fold mortality reduction with thymalin monotherapy given initially for 2–3 years. Combined protocols with epithalamin showed 4.1 fold mortality reduction.

Extended Protocol: Some practitioners use 10 mg every other day (5 mg/day effective dose) for extended 60–90 day cycles, though evidence supporting this approach is anecdotal. The RCT evidence specifically supports 10 mg daily dosing.

Anti-Inflammatory & Recovery (Injury, Infection, Post-Illness)

Acute Phase Protocol: 10–15 mg daily × 10–15 days

Extended Recovery Protocol: 10 mg daily × 20–30 days following the acute phase

Stagger Timing: Begin thymalin initiation during active inflammatory markers (elevated IL-6, CRP) or immediately post-injury. Most benefit occurs during the first 10–20 days of administration.

Evidence Context: Human observational studies show thymalin accelerated IL-6 and C-reactive protein decline in COVID-19 patients and shortened hospitalization by 11 days in burn patients. Diabetic foot wound closure time decreased from 16.3 days (control) to 12.6 days (thymalin).

Joint & Connective Tissue Support

Cycle Structure: 10 mg daily × 25 days, then 25 days off

Repeat: 3–4 cycles per year

Stack Addition: Consider stacking with other immune modulators or joint-support compounds during the "on" phase

Note: Evidence for joint health is limited (Tier 2). A human observational study involved 357 patients with arthritis and related conditions treated with thymalin as part of conventional immunomodulation, but specific thymalin efficacy was not isolated. Animal tissue culture studies show thymalin stimulates aged cartilage cell growth at 20–50 ng/ml concentrations, suggesting plausible benefit for age-related joint degeneration.

Cognitive & Neuroendocrine Function

Cycle Structure: 10 mg daily × 20–30 days, then 20–30 days off

Repeat: 2–3 cycles per year

Context: Limited human evidence (n=15 RCT in Parkinson's disease) showed thymalin improved parkinsonian symptoms and EEG markers of cortical function. A 6–8 year observational study (n=266) associated thymalin with improved nervous system function as part of homeostatic restoration, though specific cognitive metrics were not provided. Animal studies show thymalin reduced hypothalamic neuron stress sensitivity, suggesting neuroendocrine modulation.

How to Administer: Step-by-Step

Reconstitution (if supplied as powder)

1. Gather supplies: Sterile vial of thymalin powder, bacteriostatic saline (0.9% sodium chloride), sterile syringe (1–3 ml), sterile needle (25–27 gauge for drawing, 25–29 gauge for injection)
2. Determine concentration: Standard vials contain 5 or 10 mg. Check your specific product documentation.
3. Draw saline: Fill syringe with appropriate volume of bacteriostatic saline (typically 1–2 ml per 10 mg vial for a concentration of 5–10 mg/ml)
4. Inject saline: Insert needle into vial rubber septum at a slight angle. Inject saline slowly to avoid excessive pressure or foaming.
5. Dissolve: Gently roll (do not shake vigorously) the vial between your palms for 30–60 seconds until powder dissolves completely. Solution should be clear; do not use if cloudy or particles remain.
6. Draw dose: Invert vial, insert fresh needle, and draw the calculated volume for your daily dose
7. Storage post-reconstitution: Refrigerate reconstituted solution at 2–8°C; use within 14 days

Injection Technique

Site Selection: Intramuscular or subcutaneous injection into the glutes, deltoid, or outer thigh

IM Administration (preferred for faster absorption):

• Glute: Insert needle perpendicular to skin at the upper outer quadrant, approximately 3 inches below the iliac crest
• Deltoid: Insert at the center of the shoulder muscle, approximately 2–3 finger-widths below the acromion
• Insert 25-gauge needle to a depth of 1–1.5 inches at a 90-degree angle
• Aspirate (pull back on plunger) to check for blood; if blood appears, withdraw and re-site
• Inject solution slowly (over 3–5 seconds) to minimize discomfort
• Withdraw needle and apply light pressure with alcohol pad for 30 seconds

Subcutaneous Administration (gentler, longer absorption):

• Insert 27–29 gauge needle at a 45-degree angle into subcutaneous tissue of lower abdomen, upper thigh, or outer arm
• Pinch skin fold slightly to elevate subcutaneous space
• Inject slowly; subcutaneous injections may produce more localized swelling if volume is large, so limiting to 0.5–1 ml per site is advisable
• Alternate injection sites daily to minimize irritation

Storage & Stability

• Unreconstituted powder: Store at room temperature (15–25°C) or refrigerated (2–8°C); protect from light
• Reconstituted solution: Store at 2–8°C (refrigerated); do not freeze; use within 14 days of reconstitution
• Pre-filled syringes: If obtained pre-reconstituted, follow manufacturer storage guidelines; typically refrigerated
• Travel: Use an insulated cooler with ice packs if traveling; thymalin tolerates brief (2–4 hour) unrefrigerated periods

Cycle Example: Week-by-Week Schedule

20-Day On / 20-Day Off Cycle (Most Common)

30-Day On / 30-Day Off Cycle (Extended Longevity Protocol)

Dose Escalation (If Starting Lower)

Some practitioners recommend a 5-day dose escalation for individuals with sensitivity or to minimize initial immune activation symptoms:

• Days 1–5: 5 mg daily
• Days 6–20: 10 mg daily
• Days 21–40: 20 days off

What to Expect: Timeline of Effects

Days 1–3 (Initial Immune Activation)

• Injection site reactions: Mild redness, swelling, or soreness (most common with IM administration)
• Systemic symptoms: Transient low-grade fever, flu-like sensations, mild fatigue, or malaise
• Lymph node tenderness: May notice enlarged or tender lymph nodes (sign of immune cell proliferation—normal and expected)
• Action: These are expected responses. Hydration and rest accelerate symptom resolution.

Days 4–10 (Active Immune Remodeling)

• Symptom resolution: Initial fever and malaise typically resolve by day 5–7
• T-lymphocyte expansion: CD4+ and CD8+ cell populations increase; CD4+/CD8+ ratio shifts toward normal
• Cytokine modulation: IL-1, IL-2, and interferon-gamma production increases, driving anti-inflammatory and immune restoration responses
• Physical signs: Mild skin rash or urticaria possible in sensitive individuals (self-resolving)

Days 11–20 (Consolidation)

• Marker improvements: Observable improvements in immune bloodwork by days 14–20 (CD4+ counts, lymphocyte percentages, lymphocyte/neutrophil ratios)
• Symptom absence: Acute side effects typically absent by day 10
• Energy improvements: Some users report improved energy, reduced infection susceptibility, or improved recovery by day 15–20

Days 21–40 (Off-Cycle Consolidation)

• Peak effect: Immune cell populations peak approximately 3–5 days after cycle completion
• Persistent improvements: Immune gains persist and solidify during the off-cycle
• Return to baseline: Without repeated exposure, immune populations gradually normalize toward pre-protocol levels by day 40

Repeated Cycles

• Cumulative benefits: Multiple cycles produce additive immune improvements; the 6–8 year longevity study involved 2–3 years of continuous cycling
• Tolerance reduction: Cycling prevents immune system adaptation to thymalin, maintaining responsiveness across repeated administrations

Common Protocol Mistakes

Mistake 1: Continuous Daily Use Beyond 30 Days

Problem: Extended continuous use (>30 days) without breaks may lead to immune tolerance, injection site complications, and diminished responsiveness.

Correction: Adhere to 20–30 day on-cycles followed by equivalent off-cycles. This pulsed approach maintains immune reactivity.

Mistake 2: Insufficient Cycle Length

Problem: Cycles shorter than 10 days on provide insufficient time for T-lymphocyte maturation and differentiation to complete. Minimum efficacy studies show 10–20 day dosing periods.

Correction: Minimum 10 days on; 20 days on is the standard evidence-supported protocol.

Mistake 3: Neglecting Injection Site Rotation

Problem: Repeated daily injections to the same location cause persistent swelling, fibrosis, and eventual injection site complications, limiting long-term usability.

Correction: Rotate between glute, deltoid, and thigh daily. Use different sides (left vs. right). Vary IM vs. subcutaneous sites.

Mistake 4: Ignoring Initial Immune Activation Symptoms

Problem: Interpreting expected low-grade fever, malaise, or lymph node tenderness as adverse reactions leads to premature protocol discontinuation, preventing therapeutic benefits.

Correction: Expect and accept these symptoms on days 1–5. They indicate immune system engagement. Continue unless symptoms are severe or persist beyond day 7.

Mistake 5: Using Thymalin in Immunosuppressive States Without Medical Oversight

Problem: Autoimmune disease patients or transplant recipients on immunosuppression may experience adverse immune escalation or organ rejection complications.

Correction: Avoid thymalin if you have active autoimmune conditions, are an organ transplant recipient on immunosuppression, or have active hematologic malignancies. Consult a physician if any of these apply.

Mistake 6: Inconsistent Reconstitution Technique

Problem: Vigorous shaking, contamination during reconstitution, or improper storage reduces potency and increases infection risk.

Correction: Use sterile, bacteriostatic saline only. Gently dissolve powder by rolling vial, not shaking. Maintain strict aseptic technique. Refrigerate post-reconstitution.

How to Stack with Other Compounds

Thymalin's immunomodulatory mechanism makes it compatible with compounds that do not directly compete with or suppress immune function. Strategic stacking amplifies specific outcomes.

Thymalin + Epithalamin (Geroprotective Stack)

Rationale: The strongest evidence for longevity combines thymalin + epithalamin annually. Combined therapy reduced mortality 4.1-fold over 6 years vs. 2.0–2.1 fold for thymalin monotherapy.

Protocol: Cycle thymalin 10 mg daily × 30 days, then epithalamin 10 mg daily × 10 days. Rest 30 days. Repeat 2–3 times yearly.

Timing: Many practitioners administer epithalamin immediately following thymalin's off-cycle to avoid simultaneous immune stimulation.

Thymalin + Antivirals (COVID-19 / Acute Infection Stack)

Rationale: Observational studies show thymalin addition to standard therapy (antivirals, corticosteroids) accelerated IL-6 and CRP decline and reduced hospital mortality in COVID-19 (20.6% with thymalin vs. 40.9% standard therapy alone).

Protocol: 10–15 mg thymalin daily during acute illness phase (10–20 days), combined with standard antiviral therapy. Do not delay standard medical treatment for thymalin.

Timing: Start thymalin concurrently with antivirals.

Thymalin + Joint Support Agents (Connective Tissue Stack)

Rationale: Thymalin's immunomodulation combined with direct joint support (glucosamine, collagen, hyaluronic acid) addresses both inflammatory and structural aspects of joint health.

Protocol: 10 mg thymalin daily × 25 days on, paired with daily joint support supplementation. Rest 25 days. Repeat 3–4 times yearly.

Thymalin + Neuromodulators (Cognitive Stack)

Rationale: Limited